Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025Business Wire • 09/22/25
11 fast-growing small-cap stocks that could get a boost from the Fed's next moveMarket Watch • 09/15/25
FDA Files Corcept's New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian CancerBusiness Wire • 09/10/25
Corcept's Q2 Demand Grows 60%, Penetrating Large Type 2 Diabetes Market EarlySeeking Alpha • 08/08/25
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock DownZacks Investment Research • 08/01/25
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian CancerBusiness Wire • 07/14/25
Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association's 85th Scientific Sessions with Simultaneous Publication in Diabetes CareBusiness Wire • 06/23/25
Corcept: Remains A Strong Buy On Recent Weakness And Aggressive Sales Force HiringSeeking Alpha • 06/13/25
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual MeetingBusiness Wire • 06/05/25
Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian CancerBusiness Wire • 06/02/25
CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares FallZacks Investment Research • 05/06/25
CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATEBusiness Wire • 05/05/25
CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALLBusiness Wire • 04/28/25
CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025Business Wire • 04/23/25